Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-1: canakinumab plus pembrolizumab and platinum-doublet chemotherapy in first-line advanced non-small cell lung cancer
NL-OMON52694Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Recommended Phase 3 dose regimen, Progression-free survival and 1 more. Started Feb 2019; status: completed.
02
Drugs
canakinumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52694.